Global Influenza Virus Vaccine (H1N1) Market Research Report 2022

Influenza Virus Vaccine (H1N1), which is specifically designed to protect against the a (H1N1) virus, previously known as swine flu.
Due to the COVID-19 pandemic, the global Influenza Virus Vaccine (H1N1) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Influenza Virus Vaccine (H1N1) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Influenza Virus Vaccine (H1N1) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Intramuscular Vaccine accounting for % of the Influenza Virus Vaccine (H1N1) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While 3 To 10 Years Old segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Influenza Virus Vaccine (H1N1) include CSL, NVS(Novartis), Sanofi Pasteur, Medimmune, GSK, Baxter, Beijing Kexing Bio-Vaccine, Hualan Bio-Vaccine and Changchun Changsheng Bio-Technology, etc. In terms of revenue, the global 3 largest players have a % market share of Influenza Virus Vaccine (H1N1) in 2021.
This report focuses on Influenza Virus Vaccine (H1N1) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Influenza Virus Vaccine (H1N1) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Influenza Virus Vaccine (H1N1) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Intramuscular Vaccine
Nasal Spray Vaccine
Segment by Application
3 To 10 Years Old
10 To 18 Years Old
Above 18 Years Old
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
CSL
NVS(Novartis)
Sanofi Pasteur
Medimmune
GSK
Baxter
Beijing Kexing Bio-Vaccine
Hualan Bio-Vaccine
Changchun Changsheng Bio-Technology
Beijing Tiantan Bio-Products
Jiangsu Yanshen Bio-Technology
Zhejiang Tianyuan Bio-Pharmaceutical
Dalian Yalifeng Bio-Pharmaceutical
Sinopharm